- Home
- WINT vs VERO Comparison
WINT vs VERO Comparison
Compare WINT & VERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- VERO
- Stock Information
- Founded
- WINT 1992
- VERO N/A
- Country
- WINT United States
- VERO Canada
- Employees
- WINT N/A
- VERO N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- VERO Medical/Dental Instruments
- Sector
- WINT Health Care
- VERO Health Care
- Exchange
- WINT Nasdaq
- VERO Nasdaq
- Market Cap
- WINT 2.0M
- VERO 2.4M
- IPO Year
- WINT 1995
- VERO N/A
- Fundamental
- Price
- WINT $0.12
- VERO $0.33
- Analyst Decision
- WINT Hold
- VERO
- Analyst Count
- WINT 1
- VERO 0
- Target Price
- WINT $7.00
- VERO N/A
- AVG Volume (30 Days)
- WINT 7.3M
- VERO 261.4K
- Earning Date
- WINT 11-27-2024
- VERO 03-31-2025
- Dividend Yield
- WINT N/A
- VERO N/A
- EPS Growth
- WINT N/A
- VERO N/A
- EPS
- WINT N/A
- VERO N/A
- Revenue
- WINT N/A
- VERO $67,200,000.00
- Revenue This Year
- WINT N/A
- VERO N/A
- Revenue Next Year
- WINT N/A
- VERO $4.39
- P/E Ratio
- WINT N/A
- VERO N/A
- Revenue Growth
- WINT N/A
- VERO N/A
- 52 Week Low
- WINT $0.11
- VERO $0.28
- 52 Week High
- WINT $14.75
- VERO $2.22
- Technical
- Relative Strength Index (RSI)
- WINT 15.60
- VERO 45.20
- Support Level
- WINT $0.21
- VERO $0.31
- Resistance Level
- WINT $0.33
- VERO $0.39
- Average True Range (ATR)
- WINT 0.03
- VERO 0.04
- MACD
- WINT 0.00
- VERO -0.00
- Stochastic Oscillator
- WINT 2.15
- VERO 39.62
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About VERO Venus Concept Inc.
Venus Concept Inc is a medical technology company. It develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related services. The company's products include NeoGraft, Venus Viva, Venus Legacy, Venus Versa, Venus Velocity, Venus Bliss, ARTAS systems, and others. The company provides medical devices and treatments for hair, body, and skin-related problems. It generates a majority of its revenue from the United States.